Adaptive Biotechnologies (ADPT) Common Equity (2018 - 2026)

Adaptive Biotechnologies has reported Common Equity for 9 years, with the latest figure at $224.2 million in Q1 2026.

• Quarterly Common Equity rose 17.88% year-over-year to $224.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $224.2 million (up 17.88% YoY) and the FY2025 annual result came in at $225.0 million, up 11.12% from the prior year.
• Common Equity held at $224.2 million in Q1 2026 per ADPT's latest filing, from $225.0 million in the prior quarter.
• Over five years, Common Equity peaked at $553.3 million in Q1 2022 and troughed at $179.5 million in Q2 2025.
• A 5-year average of $322.3 million and a median of $274.8 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2026: Common Equity slumped 39.03% in 2024, then rose 17.88% in 2026.
• Over 5 years, Common Equity stood at $464.1 million in 2022, then slumped by 33.57% to $308.3 million in 2023, then sank by 34.32% to $202.5 million in 2024, then advanced by 11.12% to $225.0 million in 2025, then slipped by 0.34% to $224.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $224.2 million, $225.0 million, and $204.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.